February 19th, 2021, the 8th day of the first lunar year, Wuhan Healthgen Biotechnology Corp. (Hereinafter referred to as "Healthgen Biotech") had the starting ceremony of the construction of plant-derived recombinant human serum albumin core technology research project in Optics Valley BioLake. Li Feng, Deputy Director of the Administrative Committee of Wuhan East Lake High-Tech Development Zone, Deping Qian, Executive Deputy Director, and Huichen Ding, Deputy Director of Wuhan National Bio-industry Base Construction Management Office, Feng Huang, Chairman of Wuhan Hi-Tech Holding Group Co., Ltd., Daichang Yang, President & General Manager of Healthgen Biotech, Qiuping Ma, Chairman of Hubei Engineering Construction General Contracting Co., Ltd., which is the construction organization, Zhongming Yin, Deputy General Manager of Wuhan Zuoling New City Development Investment Co., Ltd., which is the project management unit, attended the ceremony.

Daichang Yang, President & General Manager of Healthgen Biotech, gave a detailed introduction to the core technology research project of plant-derived recombinant human serum albumin. This project would be Healthgen Biotech's milestone of plant-derived recombinant human serum albumin core technology, which would be vital to the development of Healthgen Biotech, and also one of the key projects of Healthgen Biotech to achieve the industrialization goal of its core product plant-derived recombinant human serum albumin. The starting ceremony of the construction marked the fast track of plant-derived recombinant human serum albumin towards industrialization. After completion of this project, it would become a benchmarking project for bio-intelligence manufacturing in Wuhan and even across China.

The project area of this time would cover 67 acres, and the investment would reach to 550 million RMB Yuan in the first stage, and the total construction area would be about 72,000 square meters. Wuhan Healthgen would plan to build a fully intelligent manufacturing project which integrates R&D center, pilot production facility and an annual production capacity of 10 tons/1 million pieces of recombinant human serum albumin cGMP production line, which is expected to be completed and put into production in March 2022.